Supernus Pharmaceuticals, Inc.
DE ˙ DB ˙ US8684591089
37,80 € 0,00 (0,00%)
2026-06-04
DEL PRIS
SecurityDE:S49 / Supernus Pharmaceuticals, Inc.
InstitutionStifel Financial Corp
Latest Disclosed Ownership60,539 shares
Latest Disclosed Value $ 3,129,246
Stifel Financial Corp reports 20.16% increase in ownership of S49 / Supernus Pharmaceuticals, Inc.

On May 12, 2026 - Stifel Financial Corp filed a 13F-HR form disclosing ownership of 60,539 shares of Supernus Pharmaceuticals, Inc. (DE:S49) valued at $2,615,285 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 50,380 shares of Supernus Pharmaceuticals, Inc.. This represents a change in shares of 20.16% during the quarter. The current value of the position is $2,288,374 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 60,539 10,159 20.16 3,129 25.01 0.0007
2026-02-13 2025-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 50,380 -12,375 -19.72 2,504 -16.54 0.0023
2025-11-12 2025-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 62,755 -839 -1.32 2,999 49.65 0.0027
2025-08-14 2025-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 63,594 -8,090 -11.29 2,005 -14.61 0.0019
2025-05-14 2025-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 71,684 3,721 5.48 2,348 -4.48 0.0025
2025-02-13 2024-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 67,963 -1,171 -1.69 2,458 14.01 0.0026
2024-11-14 2024-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 69,134 1,093 1.61 2,156 18.41 0.0023
2024-08-13 2024-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 68,041 -1,274 -1.84 1,820 -23.01 0.0020
2024-05-14 2024-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 69,315 14,862 27.29 2,364 50.10 0.0027
2024-02-12 2023-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 54,453 3,373 6.60 1,576 11.86 0.0020
2023-11-13 2023-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 51,080 9,890 24.01 1,408 13.73 0.0020
2023-08-14 2023-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 41,190 4,764 13.08 1,238 -6.14 0.0017
2023-05-12 2023-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 36,426 101 0.28 1,320 1.85 0.0019
2023-02-13 2022-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 36,325 1,979 5.76 1,296 11.35 0.0019
2022-11-14 2022-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 34,346 3,134 10.04 1,163 28.79 0.0019
2022-08-15 2022-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 31,212 3,829 13.98 903 2.03 0.0014
2022-05-13 2022-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 27,383 1,504 5.81 885 17.22 0.0012
2022-02-14 2021-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 25,879 2,794 12.10 755 22.56 0.0010
2021-11-15 2021-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 23,085 5,734 33.05 616 15.36 0.0009
2021-08-13 2021-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 17,351 2,761 18.92 534 39.79 0.0008
2021-05-14 2021-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 14,590 1,883 14.82 382 19.38 0.0006
2021-02-12 2020-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 12,707 1,296 11.36 320 34.45 0.0006
2020-11-16 2020-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 11,411 449 4.10 238 -8.46 0.0005
2020-08-14 2020-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 10,962 -1,731 -13.64 260 11.11 0.0006
2020-05-14 2020-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 12,693 -7,349 -36.67 234 -50.00 0.0006
2020-02-13 2019-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 20,042 -19,328 -49.09 468 -56.47 0.0010
2019-11-19 2019-09-30 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 39,370 -23,131 -37.01 1,075 -47.94 0.0027
2019-11-13 2019-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 37,260 -25,241 1,017 570.0795
2019-08-14 2019-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 62,501 27,962 80.96 2,065 70.10 0.0053
2019-05-14 2019-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 34,539 2,981 9.45 1,214 16.17 0.0034
2019-02-13 2018-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 31,558 -1,135 -3.47 1,045 -36.55 0.0034
2018-11-13 2018-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 32,693 -6,187 -15.91 1,647 -29.25 0.0047
2018-08-14 2018-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 38,880 -2,381 -5.77 2,328 22.66 0.0071
2018-05-11 2018-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 41,261 -4,918 -10.65 1,898 2.98 0.0060
2018-02-14 2017-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 46,179 604 1.33 1,843 0.99 0.0058
2017-11-13 2017-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 45,575 -2,930 -6.04 1,825 -12.80 0.0063
2017-08-14 2017-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 48,505 -2,796 -5.45 2,093 30.24 0.0078
2017-05-10 2017-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 51,301 831 1.65 1,607 25.74 0.0062
2017-02-16 2016-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 50,470 17,770 54.34 1,278 57.00 0.0054
2016-11-15 2016-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 32,700 -5,807 -15.08 814 3.69 0.0037
2016-08-17 2016-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 38,507 -73,703 -65.68 785 -54.12 0.0036
2016-05-16 2016-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 112,210 -15,918 -12.42 1,711 -0.64 0.0091
2016-03-21 2015-12-31 13F/A-2 SUPERNUS PHARMACEUTICALS COM 868459108 128,128 14,360 12.62 1,722 7.89 0.0090
2016-02-26 2015-12-31 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 127,583 -545 1,715 0.0090
2016-02-16 2015-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 122,715 1,788
2015-11-16 2015-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 113,768 -4,097 -3.48 1,596 -20.24 0.0090
2015-08-17 2015-06-30 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 117,865 8,533 7.80 2,001 51.36 0.0103
2015-08-17 2015-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 117,865 2,001
2015-05-14 2015-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 109,332 72,827 199.50 1,322 336.30 0.0072
2015-02-13 2014-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 36,505 250 0.69 303 -3.81 0.0017
2014-11-13 2014-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 36,255 9,450 35.25 315 7.14 0.0028
2014-08-14 2014-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 26,805 2,200 8.94 294 33.64 0.0026
2014-05-15 2014-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 24,605 24,605 220 0.0021
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.